NasdaqGS:CMAX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1,128	-62	6	17	1
12/31/2025	1,071	-103	-51	-43	3
12/31/2024	892	-144	2	11	1
3/31/2024	810	-645	-61	-49	N/A
12/31/2023	751	-683	-62	-47	N/A
9/30/2023	764	-207	-101	-91	N/A
6/30/2023	719	-126	-94	-84	N/A
3/31/2023	667	-103	-86	-78	N/A
12/31/2022	631	-38	-76	-68	N/A
9/30/2022	585	-52	-61	-55	N/A
6/30/2022	532	-44	-54	-48	N/A
3/31/2022	405	-25	-43	-39	N/A
12/31/2021	296	-7	-28	-24	N/A
9/30/2021	206	-2	-13	-9	N/A
6/30/2021	125	12	-4	-2	N/A
3/31/2021	106	6	5	7	N/A
12/31/2020	103	8	3	5	N/A
9/30/2020	101	7	5	8	N/A
12/31/2019	91	6	6	7	N/A
12/31/2018	72	3	0	1	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CMAX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CMAX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CMAX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CMAXの収益 ( 14.4% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: CMAXの収益 ( 14.4% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CMAXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

CareMax 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Price target decreased by 42% to US$26.00

Price target decreased by 17% to US$37.33

Consensus EPS estimates fall by 64%

Price target increased by 9.1% to US$6.00

Consensus EPS estimates fall by 105%

Consensus EPS estimates fall by 18%, revenue upgraded

Recent updates

High number of new directors

CareMax, Inc. announced delayed annual 10-K filing

Price target decreased by 42% to US$26.00

Price target decreased by 17% to US$37.33

CareMax Announces 1-for-30 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

CareMax Receives Non-Compliance Notice From Nasdaq

New major risk - Share price stability

New minor risk - Market cap size

Consensus EPS estimates fall by 64%

Price target increased by 9.1% to US$6.00

Consensus EPS estimates fall by 105%

New minor risk - Profitability

Caremax, Inc. Reports Unaudited Goodwill Impairment for the Three Months Ended September 30, 2023

CareMax, Inc. to Report Q3, 2023 Results on Nov 09, 2023

CareMax, Inc. Announces Resignation of David J. Shulkin as A Member of the Board of Director

Consensus EPS estimates fall by 18%, revenue upgraded

Price target decreased by 11% to US$6.00

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Caremax, Inc. Raises Revenue Guidance for the Full Year of 2023

CareMax, Inc.'s (NASDAQ:CMAX) Subdued P/S Might Signal An Opportunity

Consensus EPS estimates upgraded to US$0.28 loss, revenue downgraded

Here's What Analysts Are Forecasting For CareMax, Inc. (NASDAQ:CMAX) After Its First-Quarter Results

Caremax, Inc. Reaffirms Full Year 2023 Guidance

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$0.42 loss

Consensus EPS estimates upgraded to US$0.49 loss, revenue downgraded

Consensus revenue estimates fall by 12%

Analysts Have Just Cut Their CareMax, Inc. (NASDAQ:CMAX) Revenue Estimates By 11%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target decreased to US$8.50

CareMax, Inc. Appoints Ralph De La Torre as Director

Consensus forecasts updated

High number of new and inexperienced directors

CareMax, Inc. (NasdaqGS:CMAX) completed the acquisition of Steward National Care Network, Inc., Steward Integrated Care Network, Inc. and Steward Accountable Care Network, Inc. from Steward Health Care System LLC.

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Caremax, Inc. Raises Earnings Guidance for the Full Year 2022

CareMax, Inc. Approves Appointment of Ryan O'quinn as Board of Director

CareMax, Inc. to Report Q3, 2022 Results on Nov 09, 2022

CareMax, Inc., Annual General Meeting, Nov 02, 2022

CareMax: Numbers Are Strong, Compelling Value On Offer

Price target decreased to US$11.10

Consensus estimates of losses per share improve by 14%

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CareMax, Inc. Revises Earnings Guidance for the Full Year 2022

CareMax GAAP EPS of -$0.11 misses by $0.09, revenue of $172.28M beats by $36.85M

CareMax, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Price target decreased to US$11.00

High number of new and inexperienced directors

CareMax: Steward Health Care Acquisition Highlights Growth Ambitions

CareMax, Inc. (NasdaqGS:CMAX) entered into an agreement to acquire Steward National Care Network, Inc., Steward Integrated Care Network, Inc. and Steward Accountable Care Network, Inc. from Steward Health Care System LLC for approximately $135 million.

Consensus forecasts updated

Price target decreased to US$12.00

Caremax, Inc. Provides Earnings Outlook for the Full Year 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CareMax, Inc. to Report Q1, 2022 Results on May 10, 2022

High number of new and inexperienced directors

Consensus estimates of losses per share improve by 40%

Price target decreased to US$13.25

Consensus forecasts updated

Caremax, Inc. Provides Revenue Guidance for the Full Year 2022

Full year 2021 earnings: EPS misses analyst expectations

CareMax, Inc. to Report Q4, 2021 Results on Mar 08, 2022

CareMax, Inc. Announces Board Changes

Third quarter 2021 earnings released: US$0.035 loss per share (vs US$0.029 loss in 3Q 2020)

High number of new and inexperienced directors

CareMax: Network Of Comprehensive Care Centers Serving Medicare Beneficiaries

CareMax, Inc. announced delayed 10-Q filing

First quarter 2021 earnings released